Clinical trial
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in…
NCT00326963 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00326963 |
|---|---|
| Title | BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. |
| Official title | A Multicenter, Open-label Study Evaluating the Safety and Efficacy of a New Protease Inhibitor (Darunavir) With Fuzeon® (Enfuvirtide) Plus Background Antiretroviral Regimen in HIV-1 Infected, Triple-class Treatment-experienced Patients |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Trimeris Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Background ARVs, PI, enfuvirtide [Fuzeon] |
| Enrollment | 142 |
| Start date | Mar 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | May 1, 2007 |
| First posted | May 17, 2006 |
| Last update posted | Aug 16, 2016 |
| Countries | Australia, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: